From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

Psoriasis Fights Back

TNF-{alpha} inhibition may activate psoriasis or pustular dermatitis in some recipients.

Psoriasis often responds well to biologic inhibitors of tumor necrosis factor-{alpha} (TNF-{alpha}). Paradoxically, it also appears that psoriasis or psoriatic palmoplantar pustulosis sometimes develops in patients being treated with TNF-{alpha} inhibitors.

De Gannes and co-workers describe new-onset psoriasis (13 cases) or severe exacerbation of psoriasis (2 cases) in patients receiving TNF-{alpha} inhibitors for various rheumatologic conditions. Ubriani and Van Voorhees describe three more such cases. Add these to more than 50 other reports, and the sum suggests a causal relationship between the agents etanercept, infliximab, and adalimumab and the development of psoriasis.

What is happening? The de Gannes group suggests that interferon-{alpha} (INF-{alpha}) is involved. INF-{alpha} is an essential element in the development of early psoriasis, and TNF-{alpha} downregulates INF-{alpha} production. Therefore, the use of TNF-{alpha} inhibitory drugs neutralizes TNF-{alpha} and facilitates INF-{alpha} production, which allows psoriasis to develop.

Comment: For clinicians, several points are relevant: First, TNF-{alpha} inhibitors may precipitate psoriasis, palmoplantar pustulosis, or new-onset psoriasis, perhaps after a delay of months or years. Second, the induced psoriasis will often respond to local therapies and even to continued treatment with TNF-{alpha} inhibitors. Third, many exacerbations are pustular, and many affect the palms and soles. Fourth, this development was the exception rather than the rule. Some difference in these patients led them to develop psoriasis, and understanding this difference will probably tell us something important about the disease.

— Mark V. Dahl, MD

Published in Journal Watch Dermatology March 23, 2007

Citation(s):

de Gannes GC et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007 Feb; 143:223-31.

Ubriani R and Van Voorhees AS. Onset of psoriasis during treatment with TNF-{alpha} antagonists: A report of 3 cases. Arch Dermatol 2007 Feb; 143:270-2.

Fiorentino DF. The yin and yang of TNF-{alpha} inhibition. Arch Dermatol 2007 Feb; 143:233-6.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.